NCT01238237View on ClinicalTrials.gov

Super-Selective Intraarterial Cerebral Infusion of Cetuximab (Erbitux) for Treatment of Relapsed/Refractory GBM and AA

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

December 31, 2009

Primary Completion Date

January 31, 2016

Study Completion Date

January 31, 2016

Conditions
Glioblastoma Multiforme (GBM)ANAPLASTIC ASTROCYTOMA (AOA)GBMAnaplastic Astrocytoma
Interventions
DRUG

Superselective Intraarterial Cerebral Infusion of Cetuximab

Intraarterial Mannitol 25% 3-10 ml to open the blood brain barrier followed by Intraarterial Cetuximab single dose (starting at 100mg/m2 and escalating up to 500mg/m2)

Trial Locations (1)

10075

Lenox Hill Brain Tumor Center, New York

Sponsors

Lead Sponsor

Northwell Health
All Listed Sponsors
lead

Northwell Health

OTHER